Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Apr 12 04:00PM ET
0.3861
Dollar change
-0.0026
Percentage change
-0.67
%
Index- P/E- EPS (ttm)-0.92 Insider Own0.34% Shs Outstand10.52M Perf Week-18.11%
Market Cap4.06M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float10.49M Perf Month-45.30%
Income-6.14M PEG- EPS next Q-0.20 Inst Own3.60% Short Float1.10% Perf Quarter-55.43%
Sales0.00M P/S- EPS this Y- Inst Trans-10.38% Short Ratio0.70 Perf Half Y-31.30%
Book/sh0.24 P/B1.59 EPS next Y- ROA-51.01% Short Interest0.12M Perf Year-74.93%
Cash/sh0.80 P/C0.48 EPS next 5Y1.00% ROE-23783.30% 52W Range0.38 - 4.20 Perf YTD-49.01%
Dividend Est.- P/FCF- EPS past 5Y39.94% ROI-168.46% 52W High-90.81% Beta1.89
Dividend TTM- Quick Ratio1.55 Sales past 5Y78.49% Gross Margin-232.18% 52W Low1.61% ATR (14)0.05
Dividend Ex-Date- Current Ratio1.55 EPS Y/Y TTM80.92% Oper. Margin0.00% RSI (14)20.12 Volatility10.71% 9.14%
Employees15 Debt/Eq1.38 Sales Y/Y TTM-100.00% Profit Margin- Recom1.00 Target Price3.00
Option/ShortNo / Yes LT Debt/Eq0.44 EPS Q/Q86.53% Payout- Rel Volume1.61 Prev Close0.39
Sales Surprise19.70% EPS Surprise75.00% Sales Q/Q-100.00% EarningsMar 15 BMO Avg Volume165.01K Price0.39
SMA20-30.64% SMA50-40.65% SMA200-35.41% Trades Volume265,619 Change-0.67%
Date Action Analyst Rating Change Price Target Change
Jul-28-20Downgrade Dawson James Buy → Neutral
Jan-31-18Downgrade H.C. Wainwright Buy → Neutral $5.50 → $2.70
Aug-14-17Reiterated Maxim Group Buy $4 → $5
Jul-17-17Initiated H.C. Wainwright Buy $11
Apr-11-24 07:30AM
Apr-03-24 07:30AM
Mar-15-24 01:53PM
07:30AM
Feb-08-24 07:30AM
09:00AM Loading…
Jan-26-24 09:00AM
Jan-25-24 07:30AM
Jan-08-24 07:30AM
Jan-04-24 07:30AM
Jan-02-24 07:30AM
Dec-01-23 07:30AM
Nov-30-23 11:07AM
07:30AM
Nov-17-23 04:00PM
Nov-13-23 08:12AM
07:30AM Loading…
07:30AM
Oct-20-23 04:00PM
09:00AM
Oct-16-23 07:30AM
Oct-13-23 09:00AM
Oct-06-23 09:00AM
Sep-25-23 07:30AM
Sep-22-23 04:00PM
Aug-24-23 05:30AM
Aug-21-23 07:30AM
Aug-11-23 10:05AM
Aug-10-23 07:30AM
Jul-19-23 07:13AM
Jul-11-23 07:30AM
Jun-29-23 08:07AM
09:00AM Loading…
Jun-02-23 09:00AM
May-30-23 05:00AM
May-16-23 07:30AM
May-15-23 07:30AM
May-11-23 07:30AM
May-09-23 04:05PM
May-05-23 09:05AM
May-04-23 03:54PM
07:30AM
May-03-23 07:30AM
May-01-23 07:30AM
Apr-24-23 09:18AM
07:30AM
Apr-14-23 01:39PM
07:30AM
Apr-05-23 07:30AM
Apr-03-23 11:11AM
07:30AM
Mar-31-23 07:30AM
Mar-09-23 07:30AM
Feb-16-23 11:54AM
Feb-14-23 09:55AM
07:59AM
07:30AM
Feb-09-23 07:30AM
Jan-19-23 07:30AM
Jan-12-23 08:30AM
Jan-09-23 05:36AM
Dec-23-22 04:01PM
Dec-20-22 08:30AM
07:30AM
Dec-19-22 07:30AM
Dec-16-22 12:09PM
05:52AM
Dec-15-22 07:30AM
Dec-06-22 08:30AM
Nov-16-22 10:28AM
07:00AM
Nov-15-22 07:30AM
Nov-14-22 05:39AM
Nov-13-22 07:12AM
Nov-11-22 09:30AM
Nov-10-22 07:30AM
Nov-07-22 09:30AM
Oct-28-22 06:45AM
Oct-27-22 07:30AM
Oct-25-22 07:30AM
Oct-24-22 09:30AM
Oct-21-22 09:30AM
Oct-20-22 08:30AM
Oct-17-22 10:16AM
08:30AM
Oct-13-22 08:30AM
Sep-23-22 07:30AM
Sep-12-22 08:30AM
Sep-08-22 07:30AM
Sep-06-22 07:30AM
Aug-22-22 09:54AM
Aug-18-22 09:40AM
Aug-16-22 07:00AM
Aug-12-22 07:30AM
Jul-27-22 07:30AM
Jul-26-22 09:27AM
Jul-25-22 09:16AM
07:30AM
Jul-20-22 03:16PM
11:17AM
Jun-28-22 07:30AM
Jun-27-22 06:30AM
Jun-23-22 07:30AM
Soligenix, Inc. is a late-stage biopharmaceutical company, which engages in the development and commercialization of products to treat rare diseases. It operates through the Specialized BioTherapeutics and Public Health Solutions segments. The Specialized BioTherapeutics segment focuses on the development of a novel photodynamic therapy (SGX301) utilizing topical synthetic hypericin activated with safe visible fluorescent light for the treatment of cutaneous T-cell lymphoma. The Public Health Solutions segment consists of active development programs for RiVax, a ricin toxin vaccine candidate, and SGX943, a therapeutic candidate for antibiotic resistant and emerging infectious disease. The company was founded in 1987 and is headquartered Princeton, NJ.